Routine

Diabetes & cardiovascular risk reduction

Cardiometabolic prevention · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Type 2 diabetes markedly increases atherosclerotic and heart-failure risk. Contemporary management prioritises cardiovascular and renal protection using SGLT2 inhibitors and GLP-1 receptor agonists alongside lipid, blood-pressure and antiplatelet therapy.

Red flags

  • Symptoms of myocardial ischaemia
  • Heart failure signs (dyspnoea, oedema)
  • Rapidly rising albuminuria or falling eGFR
  • Euglycaemic ketoacidosis on SGLT2 inhibitor
  • Foot ulceration or critical limb ischaemia

Assessment

Differential diagnosis

  • Type 2 diabetes with ASCVD
  • Diabetes with heart failure
  • Diabetes with chronic kidney disease
  • Metabolic syndrome without diabetes
  • Type 1 diabetes with CV risk
  • Secondary diabetes

Investigations

  • HbA1c and renal function (eGFR, urine ACR)
  • Lipid profile
  • Blood pressure assessment
  • ECG and symptom review for CAD/HF
  • NT-proBNP or echo if heart failure suspected
  • Foot and retinal screening for microvascular disease

Management

  • Assess global cardiovascular and renal risk, not just glycaemia
  • Start an SGLT2 inhibitor for patients with ASCVD, heart failure or CKD regardless of HbA1c
  • Add a GLP-1 receptor agonist for established or high ASCVD risk, especially with obesity
  • Set an individualised HbA1c target (commonly ~53 mmol/mol / 7%)
  • Prescribe a statin for cardiovascular risk and titrate to LDL target
  • Control blood pressure, favouring ACEi/ARB with albuminuria
  • Use aspirin only for secondary prevention, not routine primary prevention
  • Reinforce weight management, diet, exercise and smoking cessation
  • Monitor renal function after starting SGLT2 inhibitor or RAAS blockade
  • Counsel on sick-day rules and euglycaemic DKA risk with SGLT2 inhibitors
  • Screen for and manage heart failure and CKD progression
  • Arrange structured multidisciplinary follow-up

Drugs & doses

Empagliflozin 10 mg PO OD (or dapagliflozin 10 mg OD) — SGLT2 inhibitor
Semaglutide SC titrated (or oral semaglutide) — GLP-1 receptor agonist
Atorvastatin 20-80 mg PO OD for lipid lowering
Ramipril 2.5-10 mg PO OD (with albuminuria/hypertension)
Metformin 500-1000 mg PO BD as glucose-lowering foundation

Disposition

GP and diabetes team shared care; cardiology/nephrology referral for established heart failure or progressive CKD.

Complications & pitfalls

  • Atherosclerotic cardiovascular events
  • Heart failure
  • Chronic kidney disease progression
  • Euglycaemic diabetic ketoacidosis (SGLT2i)
  • Hypoglycaemia from other agents

Exam pearls

  • SGLT2 inhibitors and GLP-1 agonists reduce cardiovascular events independent of glucose lowering
  • Choose the agent by the dominant risk: SGLT2i for HF/CKD, GLP-1 for atherosclerotic risk/obesity
  • Aspirin is not recommended for routine primary prevention in diabetes
  • Counsel on SGLT2-inhibitor sick-day rules to prevent euglycaemic DKA
  • Renal and cardiovascular protection now drives drug choice more than HbA1c

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.